The FDA for Doctors
Autor William H. Eaglsteinen Limba Engleză Paperback – 19 aug 2014
Preț: 351.49 lei
Preț vechi: 369.99 lei
-5% Nou
Puncte Express: 527
Preț estimativ în valută:
67.26€ • 70.76$ • 55.69£
67.26€ • 70.76$ • 55.69£
Carte tipărită la comandă
Livrare economică 14-28 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319083612
ISBN-10: 3319083619
Pagini: 97
Ilustrații: XI, 97 p. 1 illus. in color.
Dimensiuni: 155 x 235 x 12 mm
Greutate: 0.17 kg
Ediția:2014
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319083619
Pagini: 97
Ilustrații: XI, 97 p. 1 illus. in color.
Dimensiuni: 155 x 235 x 12 mm
Greutate: 0.17 kg
Ediția:2014
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Public țintă
Professional/practitionerCuprins
Introduction - The FDA, Doctors and the Practice of Medicine.- Drugs.- Devices.- Biologics.- Combination Products.- Supplements and Neutraceuticals.- Foods.- Cosmetics and Cosmeceuticals.- The FDA (history, organization, budgets).- The Approval Process (including Phases 1-4, advisory committees, Guidances and personal medicine).- The FDA and Promotion and Advertising.- The FDA and Drug Names.- The FDA , Politics and the Public.
Recenzii
“This is an excellent book that explores the question and provides many more details about the FDA. … The physician, to whom this book is directed, will learn about the regulatory process for drugs and how devices differ from drugs, nutraceuticals, and cosmeceuticals … . Dermatologists will find this book to be a fascinating excursion into another part of contemporary medicine.” (Jennifer L. Parish, SKINmed, Vol. 13 (1), January-February, 2015)
“The audience includes clinicians, policymakers, and anyone else who has an interest in how a medication comes to the marketplace. … it does an outstanding job of helping clinicians explain to their patients what they hear in the media and how a medication or device comes to market and how a medication might actually be removed from the market once FDA approval has been obtained.” (Vincent F. Carr, Doody's Book Reviews, December, 2014)
“The audience includes clinicians, policymakers, and anyone else who has an interest in how a medication comes to the marketplace. … it does an outstanding job of helping clinicians explain to their patients what they hear in the media and how a medication or device comes to market and how a medication might actually be removed from the market once FDA approval has been obtained.” (Vincent F. Carr, Doody's Book Reviews, December, 2014)
Notă biografică
Dr. Eaglstein is a medical graduate of the University of Missouri, Columbia. After an internship at Kings County Hospital in Brooklyn he completed his dermatology training at the University of Miami follow which he served in the U.S. Navy Medical Corps. He is a past professor and chairman of dermatology at the University of Pittsburgh and the University of Miami, where he is currently chairman emeritus. Since 2004 he has worked in industry at Ivax Pharmaceuticals( President of Ivax Derm), Teva and Stiefel Pharmaceuticals ( Vice President of Research ) and Stiefel a GSK company (Vice President of New Product Assessment and External Research). He is currently an independent consultant, serves on the National Institutes of Arthritis, Musculoskeletal and Skin (NIAMS) Clinical Trials Review Committee and is a volunteer for the Stanford School of Medicine SPARK program. Dr. Eaglstein has been a Robert Wood Johnson Health Policy Fellow, Chairman of an FDA skin advisory panel, Consultant to the FDA OTC division and on the NIAMS NIH National Advisory Panel. He continues his interest in health and regulatory policy. His medical/scientific interests include wound healing, wound care, drug development, skin infections, UV inflammation and inflammatory diseases such as psoriasis and acne.
Textul de pe ultima copertă
This book explains the Food and Drug Administration (FDA) as an institution and provides understanding of its nomenclature, societal role, policies, goals and challenges. While many readers will have some knowledge of the FDA, few have an appreciation of the many specific areas of FDA authority. For example, how many realize that the US is one of only two countries which allow direct-to-consumer drug advertising, which is regulated by FDA? Or that FDA itself advertises to try to prevent young people from smoking cigarettes, and that all proprietary drug names must be approved by FDA? How many doctors or other readers are familiar with the formal definition distinguishing drugs from devices and the importance this has for development costs and for our knowledge about the ultimate products? How many know how much nutritional supplements are regulated by FDA?
The FDA for Doctors is not for those looking for detailed instruction on dealing with the FDA or its operations. Rather, it is written by a doctor with doctors in mind, with the hope that the information in this book will make physicians, and other readers, more thoughtful and insightful, especially with regards to therapeutics and the many broad societal issues underlying FDA’s activities.
With over 40 years of experience as a clinical investigator in many trials done for FDA registration, the author has been a member of and chaired an FDA advisory committee, and has been a consultant to several divisions of the FDA. He has also had the opportunity to serve on the U.S. Senate Labor Committee, helping with its FDA oversight activities. In addition to a long academic medical career the author has been a consultant to and a full time employee of drug and devicecompanies.
The FDA for Doctors is not for those looking for detailed instruction on dealing with the FDA or its operations. Rather, it is written by a doctor with doctors in mind, with the hope that the information in this book will make physicians, and other readers, more thoughtful and insightful, especially with regards to therapeutics and the many broad societal issues underlying FDA’s activities.
With over 40 years of experience as a clinical investigator in many trials done for FDA registration, the author has been a member of and chaired an FDA advisory committee, and has been a consultant to several divisions of the FDA. He has also had the opportunity to serve on the U.S. Senate Labor Committee, helping with its FDA oversight activities. In addition to a long academic medical career the author has been a consultant to and a full time employee of drug and devicecompanies.
Caracteristici
Provides readers with an in-depth understanding of the FDA and those issues related to their practice and to society in general Represents an introductory overview written from a physician’s perspective for physicians Contains detailed explanation of nomenclature and definitions